<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1112246395
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIQUIN 400MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        58.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA14 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Moxiquin contains moxifloxacin as the active ingredient which belongs to a group of antibiotics called fluoroquinolones. Moxiquin works by killing bacteria that cause infections.</p><p style="text-align:justify">Moxiquin is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which moxifloxacin is active. Moxiquin should only be used to treat these infections when usual antibiotics cannot be used or have not worked:</p><p style="text-align:justify">Infection of the sinuses, sudden worsening of long term inflammation of the airways or infection of the lungs (pneumonia) acquired outside the hospital (except severe cases).</p><p style="text-align:justify">Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), includinginfections of the fallopian tubes and infections of the uterus mucous membrane.</p><p style="text-align:justify">Moxiquin tablets are not sufficient on their own for treating this kind of infection. Therefore, another antibiotic in addition to Moxiquin should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section Before taking Moxiquin).</p><p style="text-align:justify">If the following bacterial infections have shown improvement during initial treatment with Moxifloxacin Hydrochloride solution for infusion, Moxiquin may also be prescribed by your doctor to complete the course of therapy: Infection of the lungs (pneumonia) acquired outside the hospital, infections of the skin and soft tissue.</p><p style="text-align:justify">Moxiquin should not be used to initiate therapy for any type of infections of the skin and soft tissue or insevere infections of the lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Contact your doctor if you are not sure if you belong to a patient group described below.</p><p style="text-align:justify"><strong>Do not take Moxiquin tablets </strong></p><p style="text-align:justify">- If you are allergic (hypersensitive) to the active ingredient moxifloxacin, any other quinolone antibioticsor any of the other ingredients. The ingredients are listed in section 6 Further information.</p><p style="text-align:justify">- If you are pregnant or are breast-feeding.</p><p style="text-align:justify">- If you are under 18 years of age.</p><p style="text-align:justify">- If you have previously had problems with your tendons related to treatment with quinolone antibiotics</p><p style="text-align:justify">(see section Take special care &hellip; and section 4 Possible side effects).</p><p style="text-align:justify"><strong>-</strong> If you were born with or have</p><ul><li style="text-align:justify">any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart)</li><li style="text-align:justify">a salt imbalance in the blood (especially low levels of potassium or magnesium in the blood)</li><li style="text-align:justify">a very slow heart rhythm (called &lsquo;bradycardia&rsquo;)</li><li style="text-align:justify">a weak heart (heart failure)</li><li style="text-align:justify">a history of abnormal heart rhythmsor</li><li style="text-align:justify">if you are taking other medicines that result in abnormal ECG changes (see section Taking other medicines). This is because Moxiquin can cause changes on the ECG that is a prolongation of the QT-interval, i.e., delayed conduction of electrical signals.</li><li style="text-align:justify">If you have a severe liver disease or increased liver enzymes (transaminases) higher than 5 times the upper normal limit.</li></ul><p style="text-align:justify"><strong>Warnings and precautions</strong></p><p style="text-align:justify">Talk to your doctor before taking Moxiquin</p><p style="text-align:justify">- Moxiquin can change your heart&rsquo;s ECG, especially if you are female, or if you are elderly. If you are currently taking any medicine that decreases your blood potassium levels, consult your doctor before taking Moxiquin. (see also sections Do not take and Other medicines and Moxiquin).</p><p style="text-align:justify">- If you suffer from epilepsy or a condition which makes you likely to have convulsions talk to your&nbsp; doctor before taking Moxiquin.</p><p style="text-align:justify">- If you have or have ever had any mental health problems, consult your doctor before taking Moxiquin.</p><p style="text-align:justify">- If you suffer from myasthenia gravis (abnormal muscle fatigue leading to weakness and in serious cases paralysis), taking Moxiquin may worsen the symptoms of your disease. If you think you are affected consult your doctor immediately.</p><p style="text-align:justify">- If you or any member of your family have <strong>glucose-6-phosphate dehydrogenase deficiency</strong> (a rarehereditary disease), tell your doctor, who will advise whether Moxiquin is suitable for you.</p><p style="text-align:justify">- If you have a complicated infection of the female upper genital tract (e.g. associated with anabscess of the fallopian tubes and ovaries or of the pelvis), for which your doctor considers an intravenous treatment necessary, treatment with Moxiquin tablets is not appropriate.</p><p style="text-align:justify">- For the treatment of mild to moderate infections of the female upper genital tract your doctor should prescribe another antibiotic in addition to Moxiquin. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p style="text-align:justify"><strong>When taking Moxiquin</strong></p><p style="text-align:justify">- If you experience palpitations or irregular heart beat during the period of treatment, you should&nbsp;&nbsp;&nbsp; inform your doctor immediately. He/she may wish to perform an ECG to measure your heart rhythm.</p><p style="text-align:justify">- The risk of heart problems may increase with increase of the dose. Therefore, the recommended dosage should be followed.</p><p style="text-align:justify">- There is a rare chance that you may experience a severe, sudden allergic reaction (an anaphylactic reaction/shock) even with the first dose. Symptoms include tightness in the chest, feeling dizzy,feeling sick or faint, or dizziness when standing up. If so, stop taking Moxiquin and seek medical advice immediately.</p><p style="text-align:justify">- Moxiquin may cause a rapid and severe inflammation of the liver which could lead to life-threatening liver failure (including fatal cases, see section 4 Possible side effects). If you suddenly feel unwell and/or are being sick and also have yellowing of the whites of the eyes, dark urine, itching of the skin,a tendency to bleed or liver induced disease of the brain (symptoms of a reduced liver function or a rapid and severe inflammation of the liver) please contact your doctor before taking any more tablets.</p><p style="text-align:justify">- If you develop a skin reaction or blistering / peeling of the skin and/or mucosal reactions (see section 4 Possible side effects) contact your doctor immediately before you continue treatment.</p><p style="text-align:justify">- Quinolone antibiotics, including Moxiquin, may cause convulsions. If this happens, stop taking Moxiquin and contact your doctor immediately.</p><p style="text-align:justify">- You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or weakness. If this happens, inform your doctor immediately prior to continuing treatment with Moxiquin.</p><p style="text-align:justify">- You may experience mental health problems even when taking quinolone antibiotics, including Moxiquin, for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-endangering behaviour such as suicide attempts (see section 4. Possible side effects). If you develop such reactions, stop taking Moxiquin and inform your doctor immediately.&nbsp;</p><p style="text-align:justify">- You may develop diarrhoea whilst or after taking antibiotics including Moxiquin. If this becomes severe or persistent or you notice that your stool contains blood or mucus you should stop taking Moxiquin immediately and consult your doctor. You should not take medicines that stop or slow down bowel movement.&nbsp;</p><p style="text-align:justify">- Moxiquin may cause pain and inflammation of your tendons, even within 48 hours of starting treatment and up to several months after discontinuing Moxiquin therapy. The risk of inflammation and rupture of tendons is increased if you are elderly or if you are also taking corticosteroids. At the first sign of any pain or inflammation you should stop taking Moxiquin, rest the affected limb(s) and consult your doctor immediately. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture (see sections Do not take Moxiquin &hellip; and 4. Possible side effects).</p><p style="text-align:justify">- If you are elderly and have kidney problems make sure that you drink plenty whilst taking Moxiquin. If you get dehydrated this may increase the risk of kidney failure.</p><p style="text-align:justify">- If your eye sight becomes impaired or if your eyes seem to be affected whilst taking Moxiquin, consult an eye specialist immediately (see sections Driving and using machines and 4. Possible side effects).</p><p style="text-align:justify">- Fluoroquinolone antibiotics may cause disturbances in blood sugar, including both a decrease inblood sugar below normal levels (hypoglycemia) and an increase in blood sugar above normal levels(hyperglycemia). In patients treated with Moxiquin, disturbances in blood sugar occurred predominantlyin elderly patients receiving concomitant treatment with oral antidiabetic medicines that lower bloodsugar (e. g. sulfonylurea) or with insulin. If you suffer from diabetes, your blood sugar should becarefully monitored (see section 4. Possible side effects)</p><p style="text-align:justify">- Fluroquinolone antibiotics may make your skin become more sensitive to sunlight or UV light. You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or anyother UV lamp while taking Moxiquin.</p><p style="text-align:justify">- The efficacy of Moxiquin in the treatment of severe burns, infections of deep tissue and diabetic foot infections with osteomyelitis (infections of the bone marrow) has not been established.</p><p style="text-align:justify"><strong>Children and adolescents </strong></p><p style="text-align:justify">Do not give this medicine to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group (see section Do not take Moxiquin).</p><p style="text-align:justify"><strong>Taking other medicines </strong></p><p style="text-align:justify">Tell your doctor or pharmacist about any other medicines that you are taking or took recently. This includes medicines bought without a prescription.</p><p style="text-align:justify">For Moxiquin, be aware of the following:</p><p style="text-align:justify">- If you are taking Moxiquin and other medicines that affect your heart there is an increased risk foraltering your heart rhythm. Therefore, do not take Moxiquin together with the following medicines:</p><ul><li style="text-align:justify">Medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine,disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</li><li style="text-align:justify">Antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</li><li style="text-align:justify">tricyclic antidepressants.</li><li style="text-align:justify">Some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin, pentamidine,antimalarials particularly halofantrine).</li><li style="text-align:justify">Some antihistamines (e.g. terfenadine, astemizole, mizolastine).</li><li style="text-align:justify">Other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).</li></ul><p style="text-align:justify">- You must tell your doctor if you are taking other medicines that can lower your blood potassium levels(e.g. some diuretics, some laxatives and enemas [high doses] or corticosteroids [anti-inflammatory drugs], amphotericin B)or cause a slow heart rate because these can also increase the risk of serious heart rhythm disturbanceswhile taking Moxiquin.</p><p style="text-align:justify">- Any medicine containing magnesium or aluminium (such as antacids for indigestion), iron, zinc orDidanosine or any medicine containing sucralfate (to treat stomach disorders) can reduce the actionof Moxiquin tablets. Take your Moxiquin tablet 6 hours before or after taking the other medicine.</p><p style="text-align:justify">- Taking any medicine containing charcoal at the same time as Moxiquin tablets reduces the action of Moxiquin. It is recommended that these medicines are not used together.</p><p style="text-align:justify">- If you are currently taking drugs to thin your blood (oral anti-coagulants such as warfarin), it may benecessary for your doctor to monitor your blood clotting time.</p><p style="text-align:justify"><strong>Taking Moxiquin with food and drink</strong></p><p style="text-align:justify">Moxiquin can be taken with or without food (including dairy products).</p><p style="text-align:justify"><strong>Pregnancy, breast-feeding and fertility </strong></p><p style="text-align:justify">Do not take Moxiquin if you are pregnant or breast-feeding.</p><p style="text-align:justify">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="text-align:justify">Animal studies do not indicate that your fertility will be impaired by taking this medicine.&nbsp;</p><p style="text-align:justify"><strong>Driving and using machines</strong></p><p style="text-align:justify">Moxiquin may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. If you are affected do not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take Moxiquin exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p style="text-align:justify">The usual dose for adults is one 400mg film-coated tablet once daily.</p><p style="text-align:justify">Moxiquin tablets are for oral use. Swallow the tablet whole (to mask the bitter taste) and with plenty of liquid. You can take Moxiquin with or without food. Try to take the tablet at approximately the same time each day.</p><p style="text-align:justify">The same dose can be taken by elderly patients, patients with a low body weight or in patients with kidneyproblems.</p><p style="text-align:justify">The time you will take Moxiquin for depends on your infection. Unless your doctor tells you otherwise, your treatment will be as follows:</p><p style="text-align:justify">&ndash;&nbsp;&nbsp;for sudden worsening (acute exacerbation) of chronic bronchitis 5 - 10 days</p><p style="text-align:justify">&ndash;&nbsp;&nbsp;for infection of the lungs (pneumonia) except for pneumonia which starts during a stay in hospital 10 days</p><p style="text-align:justify">&ndash;&nbsp;&nbsp;for acute infection of the sinuses (acute bacterial sinusitis) 7 days</p><p style="text-align:justify">&ndash;&nbsp; Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infection of the fallopian tubes and infection of the uterus mucous membrane 14 days</p><p style="text-align:justify">It is important that you complete the course of treatment even if you begin to feel better after a few days. If you stop taking Moxiquin too soon your infection may not be completely cured and the infection may return or your condition may get worse. The bacteria causing your infection may become resistant to Moxiquin.<br />The recommended dose and duration of treatment should not be exceeded (see section Special Care)</p><p style="text-align:justify"><strong>If you take more Moxiquin than you should</strong></p><p style="text-align:justify">If you take more than the prescribed one tablet a day, get medical help immediately. Try to take any remaining tablets, the packaging or this leaflet with you to show the doctor or pharmacist what you havetaken.</p><p style="text-align:justify">I<strong>f you forget to take Moxiquin</strong></p><p style="text-align:justify">If you forget to take your tablet you should take it as soon as you remember on the same day. If you donot remember on the same day, take your normal dose (one tablet) on the next day. Do not take a doubledose to make up for a forgotten dose.</p><p style="text-align:justify">If you are unsure about what to do ask your doctor or pharmacist.</p><p style="text-align:justify"><strong>If you stop taking Moxiquin</strong></p><p style="text-align:justify">If you stop taking this medicine too soon your infection may not be completely cured. Talk to your doctor if you wish to stop taking your tablets before the end of the course of treatment.</p><p style="text-align:justify">If you have any further questions about Moxiquin, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, Moxiquin can cause side effects, although not everybody gets them. The most serious side effectsobserved during treatment with Moxiquin are listed below.</p><p style="text-align:justify">If you notice</p><ul><li style="text-align:justify">An abnormal fast heart rhythm (rare side effect) that you suddenly start feeling unwell or notice yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or disturbances of thought or wakefulness (these can be signs and symptoms of fulminant inflammation of the liver potentially leading to life-threating liver failure (very rare side effect, fatal cases have been observed)</li><li style="text-align:justify">alterations of the skin and mucous membranes like painful blisters in the mouth/nose or at the penis/vagina (Stevens-Johnson syndrome or toxic epidermal necrolysis) (very rare side effects, potentially life threatening).</li><li style="text-align:justify">inflammation of blood vessels (signs could be red spots on your skin, usually on your lower legs or effects like joint pain) (very rare side effect)</li><li style="text-align:justify">a severe, sudden generalised allergic reaction incl. very rarely a life-threatening shock (e.g. difficulty in breathing, drop of blood pressure, fast pulse) (rare side effect)</li><li style="text-align:justify">Swelling incl. swelling of the airway (rare side effect, potentially life-threatening).</li><li style="text-align:justify">convulsions (rare side effect)</li><li style="text-align:justify">troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities (rare side effect).</li><li style="text-align:justify">Depression (in very rare cases leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (rare side effect).</li><li style="text-align:justify">insanity (potentially leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (very rare side effect)</li><li style="text-align:justify">Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis incl. pseudomembranous colitis), which in very rare circumstances, may develop into complications that are life-threatening(rare side effects).</li><li style="text-align:justify">Pain and swelling of the tendons (tendonitis) (rare side effect) or a tendon rupture (very rare sideeffect).</li></ul><p style="text-align:justify">Stop taking Moxiquin and tell your doctor immediatelyas you may need urgent medical advice.</p><p style="text-align:justify">In addition, if you notice</p><ul><li style="text-align:justify">transient loss of vision (very rare side effect),</li></ul><p style="text-align:justify"><strong>Contact an eye specialist immediately</strong>.</p><p style="text-align:justify">If you have experienced life-threatening irregular heart beat (Torsade de Pointes) or stopping of heart beatwhile taking Moxiquin &nbsp;(very rare side effects), tell your treating doctor immediately that you have takenMoxiquin &nbsp;and do not restart the treatment.</p><p style="text-align:justify">A worsening of the symptoms of myasthenia gravis has been observed in very rare cases. If this happens, Consult your doctor immediately.</p><p style="text-align:justify">If you suffer from diabetes and you notice that your blood sugar is increased or decreased (rare or very rareside effect), inform your doctor immediately.</p><p style="text-align:justify">If you are elderly with existing kidney problems and you notice decrease in urine output, swelling in yourlegs, ankles or feet, fatigue, nausea, drowsiness, shortness of breath or confusion (these can be signs andsymptoms of kidney failure, a rare side effect), consult your doctor immediately.</p><p><strong>Other side effects </strong>which have been observed during treatment with Moxiquin are listed below by how likely</p><p>They are:</p><p><strong>Common </strong>(may affect up to 1 in 10 people)<br />&middot; Nausea<br />&middot; Diarrhoea<br />&middot; Dizziness<br />&middot; Stomach and abdominal ache</p><p>&middot; Vomiting<br />&middot; Headache<br />&middot; Increase of a special liver enzyme in the blood (transaminases)<br />&middot; Infections caused by resistant bacteria or fungi e.g. oral and vaginal infections caused by Candida<br />&middot; Change of the heart rhythm (ECG) in patients with low blood potassium level.</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)<br />&middot;rash<br />&middot;stomach upset (indigestion/heartburn)<br />&middot;changes in taste (in very rare cases loss of taste)<br />&middot;sleep problems (predominantly sleeplessness)<br />&middot;increase of a special liver enzyme in the blood (gamma-glutamyl-transferase and/or alkaline phosphatase)<br />&middot;low number of special white blood cells (leukocytes, neutrophils)<br />&middot;constipation<br />&middot;itching<br />&middot;sensation of dizziness (spinning or falling over)<br />&middot;sleepiness<br />&middot;wind<br />&middot;change of the heart rhythm (ECG)<br />&middot;impaired liver function (incl. increase of a special liver enzyme in the blood (LDH))<br />&middot;decreased appetite and food intake<br />&middot;low white blood cells count<br />&middot;aches and pains such as back, chest, pelvic and extremities pains<br />&middot;increase of special blood cells necessary for blood clotting<br />&middot;sweating<br />&middot;increased specialized white blood cells (eosinophils)<br />&middot;anxiety<br />&middot;feeling unwell (predominantly weakness or tiredness)<br />&middot;shaking<br />&middot;joint pain<br />&middot;palpitations<br />&middot;irregular and fast heart beat<br />&middot;difficulty in breathing incl. asthmatic conditions<br />&middot;increase of a special digestive enzyme in the blood (amylase)<br />&middot;restlessness / agitation<br />&middot;tingling sensation (pins and needles) and/or numbness<br />&middot;skin hives<br />&middot;widening of blood vessels<br />&middot;confusion and disorientation<br />&middot;decrease of special blood cells necessary for blood clotting<br />&middot;visual disturbances incl. double and blurred vision<br />&middot;decreased blood clotting<br />&middot;increased blood lipids (fats)<br />&middot;low red blood cell count<br />&middot;muscle pain<br />&middot;allergic reaction<br />&middot;increase of bilirubin in the blood<br />&middot;inflammation of the stomach<br />&middot;dehydration<br />&middot;severe heart rhythm abnormalities<br />&middot;dry skin<br />&middot;angina pectoris</p><p><strong>Rare </strong><strong>(may affect up to 1 in 1,000 people)</strong><br />&middot;muscle twitching<br />&middot;muscle cramp<br />&middot;hallucination<br />&middot;high blood pressure<br />&middot;swelling (of the hands, feet, ankles, lips, mouth, throat)<br />&middot;low blood pressure<br />&middot;kidney impairment (incl. increase in special kidney laboratory test results like urea and creatinine)<br />&middot;inflammation of the liver<br />&middot;inflammation of the mouth<br />&middot;ringing/noise in the ears<br />&middot;jaundice (yellowing of the whites of the eyes or skin)<br />&middot;impairment of skin sensation<br />&middot;abnormal dreams<br />&middot;disturbed concentration<br />&middot;difficulty in swallowing<br />&middot;changes in smell (incl. loss of smell)<br />&middot;balance disorder and poor co-ordination (due to dizziness)<br />&middot;partial or total loss of memory<br />&middot;hearing impairment including deafness (usually reversible)<br />&middot;increased blood uric acid<br />&middot;emotional instability<br />&middot;impaired speech<br />&middot;fainting<br />&middot;muscle weakness</p><p><strong>Very rare </strong>(<strong>may affect up to 1 in 10,000 people)</strong><br />&middot;inflammation of joints<br />&middot;abnormal heart rhythms<br />&middot;increase of skin sensitivity<br />&middot;a feeling of self-detachment (not being yourself)<br />&middot;increased blood clotting<br />&middot;muscle rigidity<br />&middot;significant decrease of special white blood cells (agranulocytosis) Also, there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might possibly also occur during treatment with Moxiquin :<br />&middot;Increased blood sodium levels<br />&middot;Increased blood calcium levels<br />&middot;A special type of reduced red blood cell count (haemolytic anaemia)<br />&middot;Muscle reactions with muscle cell damage<br />&middot;Increased sensitivity of the skin to sunlight or UV light</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep out of the reach and sight of children.</p><p style="text-align:justify">Do not use Moxiquin tablets after the expiry date stated on the blister and carton.</p><p style="text-align:justify">Store below 30&deg;C</p><p style="text-align:justify">Protect from light &amp; moisture.</p><p style="text-align:justify">Keep out of reach of children</p><p style="text-align:justify">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how todispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Moxiquin tablets contain</p><p>- The active substance is moxifloxacin hydrochloride. Each film-coated tablet contains 436.330mg moxifloxacin HCl Ph.Eur eq. to 400mg of Moxifloxacin.</p><p>- The other ingredients are:</p><p>Microcrystalline cellulose, Croscarmellose sodium, Silica colloidal anhydrous, povidone K-30, Magnesium stearate&amp; opadry pink 03B34285.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink coloured, capsule shaped, biconvex, film coated tablets debossed with 400 on one side and ‘MU’ on the other side

Moxiquin tablets are supplied in blister packs.
Moxiquin tablets are available in.
Box of 5 blistered tablets (1x5’s).
Box of 7 blistered tablets (1x7’s).
Box of 10 blistered tablets (1x10’s).
All Packs are not available in the marketing
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oman Pharmaceutical Products Co., LLC,</p><p>Salalah, Sultanate of Oman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">موكسيكوينيحتوي علىالعنصرالنشطموكسيفلوكساسينالذيينتميإلىمجموعةمنالمضاداتالحيويةتدعىالفلوروكينولونات . موكسيكوينيعملعنطريققتلالبكتيرياالتيتسببالالتهابات .</p><p dir="RTL">موكسيكوينيستخدمفيالمرضىالذينتتراوحأعمارهممن18سنةومافوقلعلاجالالتهاباتالبكتيريةالتاليةالتي يعتبر موكسيكويننشط ضدها. يجباستخدام موكسيكوينفقطلعلاجتلكالعدوىحيث لايمكن استخدام المضاداتالحيويةالمعتادةأوانها ليس لها اي مفعول :</p><p dir="RTL">عدوىالجيوبالأنفية،تدهورمفاجئمنالتهابطويلالأمدفيالشعبالهوائيةأوالتهابالرئتين ( ذاتالرئة) يتمالحصولعليهاخارجالمستشفى ( ماعداالحالاتالشديدة ) .</p><p dir="RTL">الالتهاباتالخفيفةالىالمعتدلةفيالمسالكالتناسليةالعلويةللأنثى (مرضالتهابالحوض ) ،بمافيذلكالتهاباتفيقناةفالوبوالتهاباتفيالغشاءالمخاطيالرحم .</p><p dir="RTL">أقراصموكسيكوينليستكافيةبمفردهالعلاجهذاالنوعمنالعدوى . ولذلك،يجبأنيوصفمضادحيويآخربالإضافةإلىموكسيكوينمنقبلالطبيبلعلاجالتهاباتالجهازالتناسليالعلويفي الإناث ( انظرالقسمقبلاتخاذموكسيكوين) .</p><p dir="RTL">إذاأظهرتالالتهاباتالبكتيريةالتاليةتحسناخلالالعلاجالأوليمعموكسيفلوكساسينهيدروكلوريدحلللتسريب،يمكنأيضاوصف موكسيكوينمنقبلالطبيبلاستكمالدورةالعلاج : العدوىفيالرئتين ( ذاتالرئة) يتمالحصولعليهاخارجالمستشفى،والتهاباتفيالجلدوالأنسجةالرخوة .</p><p dir="RTL">موكسيكوينلاينبغيأنيتستخدملبدءالعلاجلأينوعمنالتهاباتالجلدوالتهاباتالأنسجةالرخوةأوفي الالتهابات الحادة في الرئتين .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اتصلبطبيبكإذالمتكنمتأكدامماإذاكنتتنتميإلىمجموعةالمرضىالموضحينأدناه .</p><p dir="RTL"><strong>لاتتناولأقراص</strong><strong>موكسيكوين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتعانيمنحساسية ( فرط الحساسية ) لموكسيفلوكساسينالعنصرالنشط،أو أيمن المضاداتالحيويةالكينولونالأخرىأوأيمنالمكوناتالأخرى . يتمسردالمكوناتفيالقسم<strong>6 مزيدمنالمعلومات</strong> .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتحاملاأومرضعةطبيعيا .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتحتسن 18 سنةمنالعمر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكانلديكسابقامشاكلمعالأوتارالخاصةبكالمتعلقةالعلاجمعالمضاداتالحيويةالكينولون(انظرالقسم<strong>أخذ عنايةخاصة</strong> ... والقسم<strong>4 الآثارالجانبيةالمحتملة</strong> ) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتقدولدتمعأولديك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيحالةمعضرباتالقلبغيرطبيعية (توضح فيرسمالقلبالكهربائي،والتسجيلالكهربائيللقلب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدمتوازنالأملاحفيالدم (خاصةانخفاضمستوياتالبوتاسيومأوالمغنيسيومفيالدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطيءجداضرباتالقلب (وتسمى &#39; بطءدقات القلب&#39;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعففيالقلب ( قصورالقلب )</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاريخسابق فيعدمانتظامضرباتالقلب أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتأخذالأدويةالأخرىالتيتؤديإلىتغيراتغيرطبيعيةفي ECG (انظرالقسمتناولأدويةأخرى ) . وذلكلأنموكسيكوينيمكنأنيتسببفي تغيراتتخطيطالقلبالذيهوإطالةأمدQT- الفاصل،أيتأخرتوصيلالإشاراتالكهربائية .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكانلديكمرضحادفيالكبدأوزيادةإنزيماتالكبد ( الترانساميناسات ) أعلىمن 5 أضعافالحدالطبيعيالعلوي.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيراتوالاحتياطات</strong></p><p dir="RTL">تحدثمعطبيبكقبلتناولموكسيكوين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيكوينيمكنتغييرتخطيطالقلبلديك،وخاصةإذاكنتأنثى،أوإذاكنتمن المسنين . إذاكنتتأخذأيدواءحاليايخفض منمستوياتالبوتاسيومفيالدم،واستشيرالطبيبقبلاخذ موكسيكوين.(انظرأيضاالقسمين<strong>لاتأخذ</strong>و<strong>موكسيكوين</strong><strong> و الأدويةالأخرى</strong>) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتعانيمنمرضالصرعأوحالةقدتجعلكعرضةلـ التشنجاتتحدثمعطبيبكقبلتناولموكسيكوين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكانلديكأوكانلديك سابقاايمشاكلفي الصحةالعقلية،استشرطبيبكقبلاتخاذموكسيكوين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتعانيمنوهن العضلات الوخيم(تعبغيرطبيعيفيالعضلاتممايؤديإلىضعفوشللفيالحالاتالخطيرة ) ،موكسيكوينقديؤديإلىتفاقمأعراضمرضك . إذاكنتتعتقدانها تؤثرعليكاستشرالطبيبفورا .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتأنتأوأيفردمنأفرادعائلتكلديهمنقصنازعةالجلوكوز 6 فوسفات ( مرضوراثي نادر ) ،أخبرطبيبكالذيسوفينصحك إذا كان موكسيكوين مناسبلك .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكانلديكعدوىمعقدةفيالجهازالتناسليالعلويفي الاناث ( تكون مرتبطة علىسبيلالمثالبخُرَّاج&nbsp;فيقناةفالوبوالمبيضينأوفيالحوض ) ،والتيسوف يتطلب منالطبيباستخدام العلاجعنطريقالوريدوالعلاجبأقراصموكسيكوينليسمناسبا.</p><p>لعلاجالتهاباتخفيفةالىمعتدلةفيالجهازالتناسليالعلويللأنثىالطبيبيجبأنيصفمضادحيويآخربالإضافةإلىموكسيكوين . إذاكانهناكأيتحسنفيالأعراضبعد 3 أياممنالعلاج،يرجىاستشارةالطبيب .</p><p>&nbsp;</p><p dir="RTL"><strong>عندتناول</strong><strong>موكسيكوين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاواجهت<strong>الخفقانأوعدمانتظامضرباتالقلب</strong>خلالفترةالعلاج،يجبإبلاغالطبيبفورا . انه / انهاقدترغبفيإجراءتخطيطالقلبلقياسضرباتالقلبالخاصبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>خطورةمشاكلفيالقلب</strong>قدتزيدمعزيادةالجرعة . لذا،ينبغياتباعالجرعةالموصىبها .</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>هناكفرصةنادرةقدتواجهكالحساسيةالمفاجئة،الشديدة(وهيتفاعل أو صدمة رد الحساسية ) حتىمعالجرعةالأولى . وتشملالأعراضضيقفيالصدر،والشعوربالدوار،الشعوربالغثيانأوالاغماء،أوالدوخةعندالوقوف . <strong>إذاكانالأمركذلك،توقفاتخاذ</strong><strong>موكسيكوين</strong><strong>واطلبالمشورةالطبيةعلىالفور.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيكوينقديسبب<strong>التهابسريعوحادفيالكبد</strong>مماقديؤديإلىفشلالكبدوالذي قد يهددالحياة ( بمافيذلكحالاتقاتلة،انظر<strong>القسم 4 الآثارالجانبيةالمحتملة</strong> ) . إذاكنتتشعربتوعكفجأةو / أوالشعوربالمرضبالاضافة الىاصفراربياضالعينينوالبولالداكنوحكةفيالجلد،والميلإلىالنزفأوأمراضالكبدالناجمعنالدماغ ( أعراضانخفاضوظائفالكبدأوالتهابسريعوحادفيالكبد ) <strong>يرجىالاتصالالطبيبقبلتناولأيأقراصاخرى .</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاظهرت لديك<strong>ردودفعلالجلدأوظهورتقرحات / تقشيرالجلدو / أوردودفعل في الاغشيةالمخاطية</strong> (انظر<strong>القسم 4 الآثارالجانبيةالمحتملة</strong>) الاتصالبالطبيبعلىالفورقبلمواصلةالعلاج .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاداتالحيويةالكينولون،بمافيذلكموكسيكوين،قديسببالتشنجات . إذاكانهذاحدث لك،توقفاخذموكسيكوينواتصلبطبيبكفورا .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قدتواجه<strong>أعراضالاعتلالالعصبي</strong>مثلألم،حرقان،نخز،وتنميلو / أوضعف . إذاكانهذايحدث لك،إبلغالطبيبمباشرةقبلالاستمرارفيالعلاجمعموكسيكوين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قدتواجه<strong>مشكلات فيالصحةالعقلية</strong>حتىعندماتتناولالمضاداتالحيويةالكينولون،بمافيذلكموكسيكوين،للمرةالأولى . فيحالاتنادرةجداأدت الىالاكتئابأوالمشاكلالصحيةالعقليةإلىالأفكارالانتحاريةوالسلوكيةكالتفكير في انهاء الحياة مثلمحاولاتالانتحار (انظر<strong>القسم 4 . الآثارالجانبيةالمحتملة</strong> ) . إذاكان اي من هذه ظهرت لديك ،<strong>توقف عن اخذ</strong><strong>موكسيكوين</strong><strong>،وإبلغالطبيبفورا</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قديظهر لديك<strong>الإسهال</strong>فيحينأوبعدتناولالمضاداتالحيويةبمافيذلكموكسيكوين. إذاكانالاسهاليصبحشديدأومستمرأولاحظتأنالبرازيحتويعلىدمأومخاطيجب<strong>عليكالتوقفعنتناول</strong><strong>موكسيكوين</strong><strong>فوراواستشارةالطبيب</strong>. يجبأنلاتأخذالأدويةالتيتوقفأوتبطئحركةالأمعاء .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيكوينقديتسببفي <strong>الألموالتهابالأوتار</strong>الخاصةبك،حتىفيغضون 48 ساعةمنبدءالعلاجوتصلإلىعدةأشهربعدالتوقفعنبالعلاجبموكسيكوين. يتمزيادةخطرالتهابوتمزقالأوتارإذاكنت منالمسنينأوإذاكنتتأخذأيضاالكرتيكوستيرودات. فيأولبادرةمن ظهورأيألمأوالتهابيجبعليكالتوقفعنتناولموكسيكوين،اخضعالطرف او الاطرافالمصابللراحة<strong>واستشير الطبيبفورا</strong>. تجنبأيممارسةلالزوملها،لأنذلكقديزيدمنخطرتمزقالاوتار ( انظرالفرعين<strong>لاتأخذ</strong><strong>موكسيكوين</strong>... و<strong>4 . الآثارالجانبيةالمحتملة</strong> ) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتمنكبارالسنوتعانيمن<strong>مشاكلفيالكلى</strong>تأكدمنشربالكثيرمن الماء فيحينأخذموكسيكوين. إذاحصل لديك جفافهذاقديزيدمنخطرالفشلالكلوي .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذااصبح لديك ضعف في الرؤيةبالعينأوإذا<strong>كانيبدوعينيكأنتتأثر</strong>عندأخذموكسيكوين،<strong>استشيرطبيبمتخصصفيالعيونفورا</strong> (انظر<strong>قسمالقيادةواستخدامالآليات</strong>و<strong>4 الآثارالجانبيةالمحتملة</strong> ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - المضاداتالحيويةمنالفلوروكينولونقدتسبباضطراباتفيسكرالدم،بمافيذلكانخفاضسكرالدمأقلمنالمستوياتالطبيعية (نقصالسكرفيالدم) وزيادةفينسبةالسكرفيالدمأعلىمنالمستوياتالطبيعية (ارتفاعالسكرفيالدم). فيالمرضىالذينعولجوامعموكسيكوين،حدثتاضطراباتفينسبةالسكرفيالدمفيالغالبفيالمرضىالمسنينالذينيتلقونالعلاجتزامنامعالأدويةالمضادةلمرضالسكرعنطريقالفمالتيتخفضسكرالدم (مثال السلفونايليوريا ) أومعالأنسولين. إذاكنتتعانيمنمرضالسكري،يجبمراقبةمستوىالسكرفيدمكبعناية (انظرالقسم 4. الآثارالجانبيةالمحتملة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاداتالحيويةالفلوروكينولونقدتجعل<strong>بشرتك</strong>تصبحأكثرحساسية<strong>لأشعةالشمس</strong>أو<strong>الأشعةفوقالبنفسجية</strong> . يجبعليكتجنبالتعرضلفتراتطويلةلأشعةالشمسأوأشعةالشمسالقوية،وينبغيعدم اخذ حمام شمسي أواستخداممصباحالأشعةفوقالبنفسجيةعند أخذموكسيكوين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنفعاليةموكسيكوينفيعلاجالحروقالشديدة،التهاباتالأنسجةالعميقةوالتهاباتالقدمالسكريمعالتهابالعظم ( التهاباتفينخاعالعظام) لم يتم اثباتها.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفالوالمراهقين</strong></p><p dir="RTL">لاتعطيهذاالدواءإلىالأطفالوالمراهقينالذينتقلأعمارهمعن 18 لأنفعاليةوسلامةلميتم اثباتهالهذهالفئةالعمرية (انظر<strong>القسملاتأخذ</strong><strong>أوفيلوكس</strong> ) .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناولأدويةأخرى</strong></p><p dir="RTL">أخبرطبيبكأوالصيدليعنأيأدويةأخرىالتيتتخذهاأوأخذتهافيالآونةالأخيرة . وهذايشملالأدويةالتي تم شراؤهادونوصفةطبية.</p><p dir="RTL">عند استخدام موكسيكوين ، كن على علم بمايلي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذاكنتتأخذموكسيكوين والأدويةالأخرىالتيتؤثرعلىقلبكهناكخطرمتزايدفي التأثير علىإيقاعضربات قلبك . لذلك،لاتأخذموكسيكوين بالتزامن معالأدويةالتالية :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدويةالتيتنتميإلىمجموعة الأدوية المستخدمة لعلاج ضَربات القلب الغير المنتظمة (مثلكينيدين،هيدروكينيدين ، ديسوبيراميد،الأميودارون،سوتالول،الدُّوفيتيليد،إبيوتيلايد&nbsp;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاداتالذهان (مثلالفينوثيازين،بيموزيد،السرتيندول،هالوبيريدول،سولتوبرايد )</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاداتالاكتئابالثلاثيةالحلقات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعضمضاداتالميكروبات (مثلساكوينافير،السَّبارفلوكساسين،الاريثروميسين فيالوريد،بنتاميدين،الأدويةالمضادةللملارياوخاصةالهالوفانترين&nbsp;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعضمضادات الهستامين (علىسبيلالمثالتيرفينادين،استيمايزول،ميزولاستين&nbsp;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدويةالأخرى (مثلسيسابريد،فيالوريدفينكامين، بيبريدلوديفيمانيل ) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجبعليكأنتخبرطبيبكإذاكنتتأخذأدويةأخرىالتييمكنأنتؤدي الى انخفاضمستوياتالبوتاسيومفيالدم(علىسبيلالمثال،بعضمدراتالبولوبعضالأدويةالمسهلةوالحقنالشرجية [جرعاتعالية] أوالكورتيكوستيرويدات [أدويةمضادةللالتهاب] ،أمفوتيريسينب)أوتتسببفيمعدلضرباتالقلببطيئةلأنهذهيمكنأنيزيدأيضامنخطر الاصابة باضطراباتشديدةفي ضرباتالقلبفيحينأخذموكسيكوين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذ أي<strong>دواءيحتويعلىالمغنيسيومأوالألومنيوم</strong> ( مثلمضاداتالحموضةلعسرالهضم )،<strong>والحديد،والزنكأوديدانوزين</strong>أوأيدواءيحتويعلى<strong>سوكرالفات</strong>( لعلاجاضطراباتالمعدة) يمكنأنتقللمنتأثيرعمل أقراصموكسيكوين . خذقرص موكسيكوين 6 ساعات قبلأوبعدتناولالأدويةالأخرى .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذأيدواءيحتويعلى<strong>الفحم</strong>فينفسالوقتمعأقراص موكسيكوين يقللمنعمل وتأثير موكسيكوين. فمنالمستحسنأنلايتماستخدامهذهالأدويةجنباإلىجنب .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - إذاكنتتقومحاليابأخذ أدوية لزيادة سيولة الدم ( مضاداتالتخثرالفمويةمثلالوارفارين ) ،قديكونمناللازملطبيبكلمراقبةوقتكتخثرالدم .</p><p dir="RTL"><strong>أخذ موكسيكوين معالطعاموالشراب</strong></p><p dir="RTL">موكسيكوينيمكناخذهمعأوبدونالطعام (بمافيذلكمنتجاتالألبان) .</p><p dir="RTL"><strong>الحمل،والرضاعةالطبيعيةوالخصوبة</strong></p><p dir="RTL">لاتأخذيموكسيكوينإذاكنتحاملاأومرضعةطبيعيا .</p><p dir="RTL">إذاكنتحاملاأومرضعةطبيعيا،أو تعتقدين أنكقدتكونيحاملاأوتخططينلانجابطفل،إسأليطبيبكأوالصيدليللحصولعلىالمشورةقبلاتخاذهذاالدواء .</p><p dir="RTL">الدراساتعلىالحيواناتلاتشيرإلىأنالخصوبةقد تتاثر لديك عند تناولهذاالدواء .</p><p dir="RTL"><strong>القيادةواستخدامالآليات</strong></p><p dir="RTL">موكسيكوينقدتجعلكتشعربالدوارأوخفةفيالرأس،قدتحدث بشكلمفاجئ،وفقدانمؤقتللرؤيةأوقدالاغماءلفترةقصيرة . إذاظهرت لديك لا تقومبالقيادةأوتشغيلالآلات .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماخذموكسيكوينتماماكماقال لك طبيبك. يجبأنتحققمعالطبيبأوالصيدليإذاكنتغيرمتأكد .الجرعةالمعتادةللبالغينهيواحدة400 ملجم قرصمغلف بفيلممرةواحدةيوميا .</p><p dir="RTL">أقراصموكسيكوينهيللاستخدامعنطريقالفم . ابتلعقرصبأكمله ( لإخفاءالطعمالمر ) ومعالكثيرمنالسوائل . يمكنكأنتأخذموكسيكوينمعأوبدونالطعام. حاول أخذ القرص فيفينفسالوقتتقريباكليوم .</p><p dir="RTL">نفسالجرعةيمكناخذهامنقبلالمرضىكبارالسن،المرضىالذينيعانونمنانخفاضالوزنالجسمأوفيالمرضىالذينيعانونمن مشاكل فيالكلى.</p><p dir="RTL">الوقتالذيسوفتستغرقه لأخذ موكسيكوينيعتمدعلىالعدوىالموجودة لديك . مالميخبركطبيبكخلافذلك،وسوفيكونالعلاجعلىالنحوالتالي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاقم المفاجئ ( تفاقمحاد )لالتهابالشعبالهوائيةالمزمن 5-10 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعدوىفيالرئتين ( ذاتالرئة) باستثناءالالتهابالرئويالذييبدأأثناءالبقاءفيالمستشفى 10 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعدوىحادةفيالجيوبالأنفية ( التهابالجيوبالأنفيةالبكتيريالحاد) 7 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاباتفيالمسالكالتناسليةالعلوية للأنثى (مرضالتهابالحوض ) الخفيفةإلىالمعتدلة،بمافيذلكالعدوىفيقناةفالوبوالتهابفيالأغشيةالمخاطيةللرحم 14 يوما</p><p dir="RTL">منالمهمأنإكمالدورةمنالعلاجحتىلوبدأتتشعربالتحسنبعدبضعةأيام . إذاتوقفتعنتناولموكسيكوينبسرعة فأن العدوىالتي لديك قدلم يتم علاجها تماما،والعدوىقدتعودأوحالتكقدتزدادسوءا . البكتيرياالمسببةللعدوىالخاصبكقدتصبحمقاومةلموكسيكوين.</p><p dir="RTL">يجبأنلايتمتجاوزالجرعةالموصىبهاومدةالعلاج (انظر<strong>القسم</strong>عنايةخاصة ) .</p><p dir="RTL"><strong>إذاكنتتأخذأكثرممايجب</strong><strong>من موكسيكوين</strong></p><p dir="RTL">إذاكنتتأخذأكثرمنما تم وصفهلكقرصواحدفياليوم،<strong>احصلعلىالمساعدةالطبيةعلىالفور</strong> . حاول اخذأيأقراصمتبقية،أو العبوةأوهذهالنشرةمعكلاظهارها الىالطبيبأوالصيدليلتخبره ما اخذت .</p><p dir="RTL"><strong>إذاكنتقدنسيتأنتأخذ</strong><strong>موكسيكوين</strong></p><p dir="RTL">إذاكنتقدنسيتأنتأخذالقرص،يجبأن<strong>تأخذه فيأقربوقتعندماتتذكرفينفساليوم</strong> . إذالم تتذكرفينفساليوم،خذالجرعةالاعتياديةالخاصةبك ( قرصواحد ) فياليومالتالي . لاتأخذجرعة مضاعفةللتعويضعنالجرعةالمنسية.</p><p dir="RTL">إذاكنتغيرمتأكدحولمايجبفعلهاستشيرمنطبيبكأوالصيدلي .</p><p dir="RTL"><strong>إذاتوقفتعنتناول</strong><strong>موكسيكوين</strong></p><p dir="RTL">إذاتوقفتعنتناولهذاالدواءفيوقتقريبجدافان العدوى التي لديك لايتم علادها بالكامل . تحدثإلىطبيبكإذاكنتترغبفيالتوقفعنأخذأقراصالخاصبكقبلنهايةمدة العلاج .</p><p>إذاكانلديكأيأسئلةأخرىحولموكسيكوين،إسألطبيبكأوالصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثلجميعالأدوية،ويمكنأنيتسببموكسيكوينفيآثارجانبية،وإنلميكنالجميعتحصللهم . وقدتم ملاحظة الآثار الجانبية التي تم ملاحظتها أثناءالعلاجبموكسيكوين هي:</p><p dir="RTL">اذا لاحظت:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; &nbsp;إيقاعغيرطبيعيسريعللقلب (تأثيرجانبينادر) بحيثتبدأفجأةبالشعوربوعكةأوتلاحظإصفراربياضالعينين،والبولالداكن،وحكةفيالجلد،وميلإلىالنزيفأواضطراباتفيالفكرأواليقظة (يمكنأنتكونهذهعلاماتوأعراضإلتهابالكبدالتيمنالمحتملأنتؤديإلىفشلكبديهددالحياة (تأثيرجانبينادرجدا،وقدلوحظتحالاتمميتة)</li><li>&nbsp; &nbsp; &nbsp; &nbsp; تشوهاتالجلدوالأغشيةالمخاطيةمثلالبثورالمؤلمةفيالفم / الأنفأوفيالقضيب / المهبل (متلازمةستيفنزجونسونأوانحلالالبشرةالسمي) (آثارجانبيةنادرةجدا،يحتملأنتهددالحياة).</li><li>&nbsp; &nbsp; &nbsp; &nbsp; التهابالأوعيةالدموية (قدتكونالعلاماتبقعحمراءعلىبشرتك،عادةعلىساقكالسفليةأوتأثيراتمثلآلامالمفاصل) (تأثيرجانبينادرجدًا)</li><li>&nbsp; &nbsp; &nbsp; &nbsp; ردفعلتحسسيحادومفاجئعام. نادراجداصدمةتهددالحياة (علىسبيلالمثالصعوبةفيالتنفس،وانخفاضضغطالدم،نبضسريع) (الآثارالجانبيةالنادرة)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;تورم يحتوي على تورممجرىالهواء (تأثيرجانبينادر،يحتملأنيهددالحياة)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;التشنجات (الآثارالجانبيةالنادرة)</li><li>&nbsp; &nbsp; &nbsp; &nbsp; المشاكلالمرتبطةبالجهازالعصبيمثلالألموالحرقوالوخز،خدرو / أوضعففيالأطراف (تأثيرجانبينادر).</li><li>&nbsp; &nbsp; &nbsp; &nbsp; الاكتئاب (فيحالاتنادرةللغايةتؤديإلىإيذاءالذات،مثلالأفكارالانتحارية / التصور،أومحاولاتالانتحار) (الآثارالجانبيةالنادرة).</li><li>&nbsp; &nbsp; &nbsp; الجنون (منالمحتملأنيؤديإلىإيذاءالذات،مثلالأفكارالانتحارية /&nbsp; التصورأومحاولاتالانتحار) (تأثيرجانبينادرجدًا)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;الإسهالالشديدالذييحتويعلىالدمو / أوالمخاط (التهابالقولونالمرتبطبالمضاداتالحيويةبمافيذلكالتهابالقولونالغشائيالكاذب) ،والذيقديتطورفيحالاتنادرةجداًإلىمضاعفاتتهددالحياة (آثارجانبيةنادرة).</li><li>&nbsp; &nbsp; &nbsp; &nbsp; الألموتورمالأوتار (التهابالأوتار) (أثرجانبينادر) أوتمزقالأوتار (تأثيرجانبينادرجدا).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقفعنتناول</strong><strong>موكسيكوين</strong><strong>وأخبرطبيبكعلىالفور</strong>حيثقدتحتاجإلىنصيحةطبيةعاجلة.</p><p dir="RTL">بالإضافةإلىذلك،إذالاحظت</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; &nbsp; فقدانالبصرالمؤقت (تأثيرجانبينادرجدًا) ،<strong>اتصلبأخصائيالعيونعلىالفور.</strong></li></ul><p dir="RTL">إذاكنتقدعانيتمنضرباتالقلبغيرالمنتظمةالتيتهددالحياة (Torsade de Pointes) أوالتوقفعنضرباتالقلبأثناءتناولموكسيكوين (آثارجانبيةنادرةجدًا) ،<strong>أخبرالطبيبالمعالجفورًابأنكقدتناولت</strong><strong>موكسيكوين</strong><strong>وعدمإعادةالعلاج.</strong></p><p dir="RTL">وقدلوحظتفاقمأعراضالوهنالعضليالوبيلفيحالاتنادرةجدا. اذاحدثهذا،<strong>استشرطبيبكعلىالفور.</strong></p><p dir="RTL">إذاكنتتعانيمنمرضالسكريوتلاحظأننسبةالسكرفيالدمتزدادأوتنخفض (تأثيرنادرأونادرجدًا) ،<strong>أخبرطبيبكعلىالفور</strong>.</p><p dir="RTL">إذاكنتمنكبارالسنيعانونمنمشاكلفيالكلىموجودةوتلاحظانخفاضفيإنتاجالبول،أوتورمفيساقيك،أوكاحليكأوقدميك،أوتعب،أوغثيان،أونعاس،أوضيقفيالتنفسأوالارتباك (يمكنأنتكونهذهعلاماتوأعراضللفشلالكلوي،وهوتأثير جانبينادر) ،<strong>استشرطبيبكعلىالفور.</strong></p><p dir="RTL"><strong>الآثارالجانبيةالأخرى</strong>التيلوحظتأثناءالعلاجمعموكسيكوينمذكورةأدناهحسبمدىاحتماليةحدوثها وهي :</p><p dir="RTL"><strong>الشائعة</strong> (تؤثرعلىأكثرمن 1 مستخدمفي كل 10 من اشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلامفيالمعدةوالبطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداعالراس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةإنزيمكبدي خاص فيالدم (الترانساميناسات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاباتالتيتسببهاالبكتيرياأوالفطرياتالمقاومة،علىسبيلالمثال. الإصاباتالفمويةوالمهبليةالتيتسببهاكانديدا&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرإيقاعالقلب (ECG) فيالمرضىالذينيعانونمنانخفاضمستوىالبوتاسيومفيالدم.</p><p dir="RTL"><strong>الغيرشائعة</strong> (قديؤثرعلىشخصواحدمنبينكل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلبات في المعدة&nbsp; (عسرالهضم / حرقةالفؤاد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيراتفيالمذاق (فيحالاتنادرةجدافقدانالذوق)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكلفيالنوم (يغلبعليهاالأرق)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةإنزيمكبديخاصفيالدم (جاما-غلوتاميلترانسفيرازو / أوالفوسفاتيز القلوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عددخلاياالدمالبيضاءالخاصة (الكرياتالبيضاء،العدلات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الامساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحساسبالدوخة (الدوارأوالسقوط)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغازات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرإيقاعالقلب (ECG)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في وظيفةالكبد (بمافيذلكزيادةإنزيمالكبدالخاصفيالدم (LDH))</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضالشهيةوتناولالطعام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض فيعددخلاياالدمالبيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعبوآلاممثلآلامالظهروالصدروالحوضوالأطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةخلاياالدمالخاصةاللازمةلتخثرالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خلاياالدمالبيضاءالمتخصصة (الأحماض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعوربالإعياء (غالباًمايكونالضعفأوالتعب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمالمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضرباتالقلبالسريعة والغير منتظمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبةفيالتنفسبمافيذلك حالةالربو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةإنزيمهضميخاصفيالدم (الأميليز)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدمالاستقرار / الإثارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساسبالوخز (دبابيسوالإبر) و / أوخدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع فيالأوعيةالدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الادراكوالارتباك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض فيخلاياالدمالخاصةاللازمةلتخثرالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطراباتالنفسيةبمافيذلكضعفوضوحالرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخثرالدمبشكلملحوظ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل الدهون فيالدم (الدهون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عددخلاياالدمالحمراء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمفيالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردفعلتحسسي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةالبيليروبينفيالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهابالمعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظامفي إيقاعالقلببشكل حاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلدالجاف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذبحةالصدرية</p><p dir="RTL"><strong>النادرة (قدتؤثرعلى 1 منكل 1000 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرتعاشالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغطالدمالمرتفع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (فياليدينوالقدمينوالكاحلينوالشفتينوالفموالحلق)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغطالدمالمنخفض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعفالكُلى (بمافيذلكالزيادةفينتائجالاختباراتالمعمليةالخاصةبالكليةمثلاليورياوالكرياتينين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابالكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابالفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين / ضجيجفيالأذنين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفراربياضالعينأوالجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعفالإحساسبالجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلامغيرطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيزمضطرب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبةفيالبلع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيراتفيالرائحة (بمافيذلكفقدانالرائحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابالتوازنوسوءالتنسيق (بسببالدوخة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدانجزئيأوكليللذاكرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعفالسمعبمافيذلكالصمم (يمكنعكسهعادة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةحمضاليوريكفيالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدمالاستقرارالعاطفي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الكلام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعفالعضلات</p><p dir="RTL"><strong>النادرةجدًا (قديؤثرعلىشخصواحدمنبينكل 10000 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابالمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدمانتظامضرباتالقلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةحساسيةالجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعوربالانفصالعنالذات (لست كالمعتاد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةتخثرالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صلابةالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضكبيرفيخلاياالدمالبيضاءالخاصة (ندرةالمحببات)</p><p dir="RTL">أيضا،كانتهناكحالاتنادرةجدامنالآثارالجانبيةالتاليةذكرتبعدالعلاجمعغيرها</p><p dir="RTL">المضاداتالحيويةالكينولون،والتيقدتحدثأيضًاأثناءالعلاجمعموكسيكوين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةمستوياتالصوديومفيالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةمستوياتالكالسيومفيالدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوعخاصمنانخفاضعددخلاياالدمالحمراء (فقرالدمالانحلالي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردودفعلالعضلاتمعتلفخلاياالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادةحساسيةالجلدلأشعةالشمسأوالأشعةفوقالبنفسجية</p><p dir="RTL"><strong>الإبلاغعنالآثارالجانبية</strong></p><p>إذاحصلتعلىأيآثارجانبية،تحدثمعطبيبكأوالصيدليأوالممرضة. يتضمنذلكأيآثارجانبيةمحتملةغيرمدرجةفيهذهالنشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظبعيداعنمتناولوبصرالأطفال .</p><p dir="RTL">لاتستخدمأقراصموكسيكوينبعدتاريخانتهاءالصلاحيةالمذكورعلىالشريطوالعبوة .</p><p dir="RTL">يخزنفي درجة حرارة أقلمن 30 درجةمئوية</p><p dir="RTL">يحفظبعيداعنالضوءوالرطوبة.</p><p dir="RTL">لاينبغيالتخلصمنالأدويةعنطريقمياهالصرفالصحيأوالنفاياتالمنزلية . اسألالصيدليكيفية</p><p>التخلصمنالأدويةالتيلمتعدمطلوبة . وسوفتساعدهذهالتدابيرلحمايةالبيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">علىماذاتحتويأقراصموكسيكوين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادةالنشطةموكسيفلوكساسينهيدروكلوريد . كلقرصمغلف بفلم يحتويعلى 436.330 ملجمموكسيفلوكساسينهيدروكلوريدPh.Eurمكافئ . إلى400 ملجممنموكسيفلوكساسين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكوناتالأخرىهي:</p><p dir="RTL">&nbsp;ميكروكريستالين السليلوز، كروسكارميلوزالصوديوم،السيليكاالغرويةاللامائي،البوفيدونK -30،المغنيسيومستيراتواوبدريالوردي34285B03.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">اقراص وردية اللون ، محدبة الشكل تشبه الكبسول مغلفة بالفيلم طبعت على الاقراص احد جانبيها) 400( والجانب الاخر (MU)</p><p dir="RTL" style="text-align:right">يتمتوفيرأقراصموكسيكوينفي عبوة تحتوي على شريط .</p><p dir="RTL" style="text-align:right">عبوة تحتوي على 5اقراص في شريط(1x5&rsquo;s).</p><p dir="RTL" style="text-align:right">عبوة تحتوي على 7اقراص في شريط(1x7&rsquo;s).</p><p dir="RTL" style="text-align:right">عبوة تحتوي على &nbsp;10 اقراص في شريط(1x10&rsquo;s)..</p><p style="text-align:right">لا يتم تسويق جميع العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركةالمصنعة وصاحبة حقوق التسويق</strong></p><p dir="RTL">زينوفا/ الشركة العمانية لمستحضرات الصيدلة ش.م.م</p><p dir="RTL">&nbsp;صلالة،سلطنةعمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخالنشرة: مارس 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moxiquin 400 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 400 mg Moxifloxacin (as hydrochloride). For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
Pink colored, capsule shaped, biconvex, film coated tablets, debossed with “400” on one side and “MU” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Moxiquin 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:</p><p style="text-align:justify">-&nbsp; Acute bacterial sinusitis (adequately diagnosed)</p><p style="text-align:justify">-&nbsp; Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p style="text-align:justify">-&nbsp; Community acquired pneumonia, except severe cases</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.</p><p style="text-align:justify">Moxiquin 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxifloxacin resistance&nbsp; of <em>Neisseria gonorrhoeae </em>unless moxifloxacin-resistant <em>Neisseria gonorrhoeae </em>can be excluded (see sections 4.4 and 5.1).</p><p style="text-align:justify">Moxiquin 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications:</p><p style="text-align:justify">-&nbsp; Community-acquired pneumonia</p><p style="text-align:justify">-&nbsp; Complicated skin and skin structure infections</p><p style="text-align:justify">Moxiquin 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.</p><p style="text-align:justify">Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Posology (adults)</u></p><p style="text-align:justify">The recommended dose is one 400 mg film-coated tablet once daily.</p><p style="text-align:justify"><em>Renal/hepatic impairment</em></p><p style="text-align:justify">No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).</p><p style="text-align:justify">There is insufficient data in patients with impaired liver function (see section 4.3).</p><p style="text-align:justify"><em>Other special populations</em></p><p style="text-align:justify"><em>&nbsp;</em>No adjustment of dosage is required in the elderly and in patients with low bodyweight.</p><p style="text-align:justify"><em>Paediatric population</em></p><p style="text-align:justify"><em>&nbsp;</em>Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p style="text-align:justify"><u>Method of administration</u></p><p style="text-align:justify">The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p><u>Duration of administration</u></p><p>Moxiquin 400 mg film-coated tablets should be used for the following treatment durations:</p><p>-&nbsp; Acute exacerbation of chronic bronchitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 - 10 days</p><p>-&nbsp; Community acquired pneumonia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 days</p><p>-&nbsp; Acute bacterial sinusitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7 days</p><p>-&nbsp; Mild to moderate pelvic inflammatory disease&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 days</p><p style="text-align:justify">Moxiquin 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.</p><p style="text-align:justify"><em>Sequential (intravenous followed by oral) therapy</em></p><p style="text-align:justify">In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections</p><p style="text-align:justify">The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients listed in section 6.1.
-	Pregnancy and lactation (see section 4.6).
-	Patients below 18 years of age.
-	Patients with a history of tendon disease/disorder related to quinolone treatment.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to moxifloxacin, in the form of QT prolongation. For reasons of drug safety, moxifloxacin is therefore contraindicated in patients with:
-	Congenital or documented acquired QT prolongation
-	Electrolyte disturbances, particularly in uncorrected hypokalaemia
-	Clinically relevant bradycardia
-	Clinically relevant heart failure with reduced left-ventricular ejection fraction
-	Previous history of symptomatic arrhythmias
Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).

Due to limited clinical data, moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS</strong></p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp; Fluoroquinolones, including MOXIQUIN, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including:</p><p style="text-align:justify">o&nbsp; Tendinitis and tendon rupture.</p><p style="text-align:justify">o&nbsp; Peripheral neuropathy.</p><p style="text-align:justify">o&nbsp; Central nervous system effects.</p><p style="text-align:justify">Discontinue&nbsp;&nbsp;&nbsp; MOXIQUIN &nbsp;immediately&nbsp; &nbsp;and&nbsp;&nbsp; avoid&nbsp;&nbsp; the&nbsp;&nbsp; use&nbsp; &nbsp;of&nbsp;&nbsp; fluoroquinolones,&nbsp;&nbsp;&nbsp; including MOXIQUIN, in patients who experience any of these serious adverse reactions.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp; Fluoroquinolones, including MOXIQUIN, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid MOXIQUIN in patients with known history of myasthenia gravis.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp; Because fluoroquinolones, including MOXIQUIN, have been associated with serious adverse reactions, reserve MOXIQUIN for use in patients who have no alternative treatment options for the following indications:</p><p style="text-align:justify">o&nbsp; Acute bacterial sinusitis</p><p style="text-align:justify">o&nbsp; Acute bacterial exacerbation of chronic bronchitis</p><p style="text-align:justify">The benefit of moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section.</p><p style="text-align:justify"><u>Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions</u></p><p style="text-align:justify">Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.</p><p style="text-align:justify">Medication that can reduce potassium levels should be used with caution in patients receiving moxifloxacin (see also sections 4.3 and 4.5).</p><p style="text-align:justify">Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded.</p><p style="text-align:justify">If signs of cardiac arrhythmia occur during treatment with moxifloxacin, treatment should be stopped and an ECG should be performed.</p><p style="text-align:justify"><u>Hypersensitivity/allergic reactions</u></p><p style="text-align:justify">Hypersensitivity and allergic reactions have been reported for fluoroquinolones including moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.</p><p style="text-align:justify"><u>Severe liver disorders</u></p><p style="text-align:justify">Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with moxifloxacin (see section 4.8). Patients should be advised to contact their doctor</p><p style="text-align:justify">prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.</p><p style="text-align:justify">Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.</p><p style="text-align:justify"><u>Serious bullous skin reactions</u></p><p style="text-align:justify">Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with moxifloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p style="text-align:justify"><u>Patients predisposed to seizures</u></p><p style="text-align:justify">Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with moxifloxacin should be discontinued and appropriate measures instituted.</p><p style="text-align:justify"><u>Peripheral neuropathy</u></p><p style="text-align:justify">Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including moxifloxacin. Patients under treatment with moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop (see section 4.8).</p><p style="text-align:justify"><u>Psychiatric reactions</u></p><p style="text-align:justify">Psychiatric reactions may occur even after the first administration of quinolones, including moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, moxifloxacin should be discontinued and appropriate measures instituted. Caution is recommended if moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p style="text-align:justify"><u>Antibiotic-associated diarrhoea incl. colitis</u></p><p style="text-align:justify">Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of broad spectrum antibiotics including moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of moxifloxacin. If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately.</p><p style="text-align:justify">Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.</p><p style="text-align:justify"><u>Patients with myasthenia gravis</u></p><p style="text-align:justify">Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.</p><p style="text-align:justify"><u>Tendon inflammation, tendon rupture</u></p><p style="text-align:justify">Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with moxifloxacin, rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon. (see sections 4.3 and 4.8)..</p><p style="text-align:justify"><u>Patients with renal impairment</u></p><p style="text-align:justify">Elderly patients with renal disorders should use moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.</p><p style="text-align:justify"><u>Vision disorders</u></p><p style="text-align:justify">If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p style="text-align:justify"><u>Dysglycemia</u></p><p style="text-align:justify">As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycemia, hyperglycemia have been reported with Moxifloxacin. In Moxifloxacin-treated patients, dysglycemia occured predominately in elderly diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g. sulfonylurea) or with insulin. In diabetic patients, careful monitoring of blood glucose is recommended (see sections 4.8).</p><p style="text-align:justify"><u>Prevention of photosensitivity reactions</u></p><p style="text-align:justify">Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with moxifloxacin.</p><p style="text-align:justify"><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u></p><p style="text-align:justify">Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, moxifloxacin should be used with caution in these patients.</p><p style="text-align:justify"><u>Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption</u></p><p style="text-align:justify">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p style="text-align:justify"><u>Patients with pelvic inflammatory disease</u></p><p style="text-align:justify">For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with Moxiquin 400 mg film-coated tablets is not recommended.</p><p style="text-align:justify">Pelvic inflammatory disease may be caused by fluoroquinolone-resistant <em>Neisseria gonorrhoeae</em>. Therefore in such cases empirical moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless moxifloxacin-resistant <em>Neisseria&nbsp; gonorrhoeae </em>can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p style="text-align:justify"><u>Patients with special cSSSi</u></p><p style="text-align:justify">Clinical efficacy of intravenous moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p style="text-align:justify"><u>Interference with biological tests</u></p><p style="text-align:justify">Moxifloxacin therapy may interfere with the <em>Mycobacterium </em>spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving moxifloxacin.</p><p style="text-align:justify"><u>Patients with MRSA infections</u></p><p style="text-align:justify">Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p style="text-align:justify"><u>Paediatric population</u></p><p style="text-align:justify">Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Interactions with medicinal products</u></p><p style="text-align:justify">An additive effect on QT interval prolongation of moxifloxacin and other medicinal products&nbsp; that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):</p><p style="text-align:justify">-&nbsp; anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)</p><p style="text-align:justify">-&nbsp; anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p style="text-align:justify">-&nbsp; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p style="text-align:justify">-&nbsp; tricyclic antidepressive agents</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)</p><p style="text-align:justify">-&nbsp; certain antihistaminics (terfenadine, astemizole, mizolastine)</p><p style="text-align:justify">-&nbsp; others (cisapride, vincamine IV, bepridil, diphemanil).</p><p style="text-align:justify">Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.</p><p style="text-align:justify">An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations (e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of moxifloxacin.</p><p style="text-align:justify">Concomitant administration of charcoal with an oral dose of 400 mg moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).</p><p style="text-align:justify">After repeated dosing in healthy volunteers, moxifloxacin increased C<sub>max</sub> of digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.</p><p style="text-align:justify">In studies conducted in diabetic volunteers, concomitant administration of oral moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic</p><p style="text-align:justify">parameters (blood glucose, insulin). Therefore no clinically relevant interaction was observed between moxifloxacin and glibenclamide.</p><p style="text-align:justify"><em>Changes in INR</em></p><p style="text-align:justify"><em>&nbsp;</em>A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.</p><p style="text-align:justify">Clinical studies have shown no interactions following concomitant administration of moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.</p><p style="text-align:justify"><em>In vitro </em>studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.</p><p style="text-align:justify"><u>Interaction with food</u></p><p style="text-align:justify">Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Pregnancy</u></p><p style="text-align:justify">The safety of moxifloxacin in human pregnancy has not been evaluated.. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, moxifloxacin must not be used in pregnant women (see section 4.3).</p><p style="text-align:justify"><u>Breastfeeding</u></p><p style="text-align:justify">There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during moxifloxacin therapy (see section 4.3).</p><p style="text-align:justify"><u>Fertility</u></p><p style="text-align:justify">Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No studies on the effects of moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>To report any side effect(s):</strong></p><ul><li><strong>Saudi Arabia</strong></li></ul><p><strong>National Pharmacovigilance &amp; Drug Safety Centre (NPC)</strong></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p><ul><li><strong>Other GCC states:</strong></li></ul><p><strong>Please contact the relevant competent authority</strong></p><p>Adverse reactions based on all clinical trials with moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below:</p><p>Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as:</p><p>- common (&ge; 1/100 to &lt; 1/10)</p><p>- uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>- rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>- very rare (&lt; 1/10,000)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System&nbsp;&nbsp;&nbsp;&nbsp; Organ Class (MedDRA)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections&nbsp;&nbsp;&nbsp;&nbsp; and infestations</strong></p></td><td style="vertical-align:top"><p>Superinfections due to resistant bacteria or fungi</p><p>e.g.&nbsp;&nbsp;&nbsp;&nbsp; oral&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia Leucopenia(s) Neutropenia Thrombocytopenia Thrombocythemia Blood eosinophilia</p><p>Prothrombin time prolonged/INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin level increased/INR decreased</p><p>&nbsp;</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic&nbsp;&nbsp;&nbsp;&nbsp; reaction (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl. very rarely life-threatening shock (see section 4.4)</p><p>Allergic oedema /&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiooedema (incl.&nbsp;&nbsp;&nbsp;&nbsp; laryngeal oedema, potentially&nbsp;&nbsp;&nbsp; life- threatening,&nbsp;&nbsp;&nbsp; see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia</p><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>&nbsp;</p><p>Psychomotor hyperactivity/ agitation</p></td><td style="vertical-align:top"><p>Emotional lability</p><p>Depression&nbsp;&nbsp;&nbsp; (in very rare cases potentially culminating&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in self-injurious behaviour, such as suicidal ideations/ thoughts,&nbsp; or suicide attempts, see section 4.4)</p><p>Hallucination</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>Psychotic reactions (potentially culminating in self- injurious behaviour, such assuicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Par- and</p><p>Dysaesthesia</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders (incl. ageusia in very rare cases)</p></td><td style="vertical-align:top"><p>Smell&nbsp;&nbsp;&nbsp; disorders (incl. anosmia)</p><p>Abnormal dreams</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusion&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and disorientation</p><p>Sleep disorders (predominantly insomnia)</p><p>Tremor</p></td><td style="vertical-align:top"><p>Disturbed coordination (incl.&nbsp;&nbsp;&nbsp;&nbsp; gait disturbances, esp. due&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to Dizziness or vertigo)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo Somnolence</p></td><td style="vertical-align:top"><p>Seizures incl. grand&nbsp;&nbsp;&nbsp;mal convulsions (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disturbed attention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Speech disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amnesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral neuropathy&nbsp;&nbsp;&nbsp; and polyneuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual&nbsp; isturbances incl. diplopia&nbsp;&nbsp;&nbsp; and blurred&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision (especially in the course of CNS reactions, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient loss of vision (especially in the course of CNS reactions, see sections 4.4</p><p>and 4.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>QT prolongation in patients with hypokalaemia (see sections 4.3 and 4.4)</p></td><td style="vertical-align:top"><p>QT&nbsp;&nbsp;&nbsp;&nbsp; prolongation (see section 4.4)</p><p>Palpitations Tachycardia Atrial fibrillation Angina pectoris</p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmias</p><p>Syncope (i.e., acute and short lasting loss of consciousness)</p></td><td style="vertical-align:top"><p>Unspecified arrhythmias</p><p>Torsade de</p><p>Pointes (see section 4.4)</p><p>Cardiac&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arrest (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea (including asthmatic conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea Vomiting</p><p>Gastrointestinal and&nbsp;&nbsp;&nbsp;&nbsp; abdominal pains</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased appetite and food intake</p><p>Constipation Dyspepsia Flatulence Gastritis Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia Stomatitis</p><p>Antibiotic associated colitis (incl.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pseudo- membranous colitis,&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp; very rare&nbsp;&nbsp;&nbsp;cases associated&nbsp;&nbsp;&nbsp;&nbsp; with life-threatening complications, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Increase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment&nbsp;&nbsp;&nbsp; (incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased gamma- glutamyl- transferase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="vertical-align:top"><p>Fulminant hepatitis potentially leading to life- threatening liver failure (incl. fatal cases, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bullous skin</p><p>Reactions like Stevens-Johnson syndrome or toxic epidermal &nbsp;ecrolysis (potentially life- threatening, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and&nbsp;&nbsp;&nbsp;connective</strong></p><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis&nbsp;&nbsp;&nbsp;&nbsp; (see section 4.4)</p></td><td style="vertical-align:top"><p>Tendon&nbsp;&nbsp;&nbsp;&nbsp; rupture (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle cramp</p></td><td style="vertical-align:top"><p>Arthritis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle twitching</p></td><td style="vertical-align:top"><p>Muscle rigidity</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle weakness</p></td><td style="vertical-align:top"><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment (incl. increase in BUN and creatinine)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal&nbsp; failure (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia or fatigue) Feeling unwell (predominantly</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sweating</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p style="text-align:justify">There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with moxifloxacin: hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Quinolone antibacterials, fluoroquinolones, ATC code: J01MA14</p><p style="text-align:justify"><u>Mechanism of action</u></p><p style="text-align:justify">Moxifloxacin has <em>in vitro </em>activity against a wide range of Gram-positive and Gram-negative pathogens.</p><p style="text-align:justify">The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <em>nor</em>A or <em>pmr</em>A genes seen in certain Gram-positive bacteria.</p><p style="text-align:justify">Pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</p><p style="text-align:justify"><u>Effect on the intestinal flora in humans</u></p><p style="text-align:justify">The following changes in the intestinal flora were seen in volunteers following oral administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moxifloxacin:<em>Escherichia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coli</em>, <em>Bacillus </em>spp., <em>Enterococcus </em>spp., and <em>Klebsiella </em>spp.&nbsp;&nbsp;&nbsp;&nbsp; were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaerobes<em>Bacteroides&nbsp;&nbsp;&nbsp; vulgatus</em>, <em>Bifidobacterium </em>spp., <em>Eubacterium </em>spp., and <em>Peptostreptococcus </em>spp.. For <em>Bacteroides fragilis</em>there was an increase. These changes returned to normal within two weeks.</p><p style="text-align:justify"><u>Mechanism of resistance</u></p><p style="text-align:justify">Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of moxifloxacin. Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also effect susceptibility to moxifloxacin.</p><p style="text-align:justify"><em>In vitro </em>resistance to moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.</p><p style="text-align:justify">Cross-resistance is observed with other fluoroquinolones. However, as moxifloxacin inhibits both topoisomerase II and IV with similar activity in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to moxifloxacin.</p><p style="text-align:justify"><u>Breakpoints</u></p><p style="text-align:justify">EUCAST clinical MIC and disk diffusion breakpoints for moxifloxacin (01.01.2011):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&ge; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>Groups A, B, C, G</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&ge; 23 mm</p></td><td style="vertical-align:top"><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints*</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p></td></tr></tbody></table><p><u>Microbiological Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Gardnerella vaginalis</em></p><p><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p><em>Streptococcus agalactiae </em>(Group B)</p><p><em>Streptococcus milleri </em>group* (<em>S. anginosus, S. constellatus and S. intermedius</em>) <em>Streptococcus pneumoniae</em>*</p><p><em>Streptococcus pyogenes</em>* (Group A)</p><p><em>Streptococcus viridans </em>group <em>(S. viridans, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilus)</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumanii Haemophilus influenzae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus parainfluenzae</em>* <em>Legionella pneumophila</em></p><p><em>Moraxella (Branhamella) catarrhalis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Fusobacterium </em>spp.</p><p><em>Prevotella </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>&ldquo;Other&rdquo; micro-organisms</u></p><p><em>Chlamydophila (Chlamydia) pneumoniae</em>* <em>Chlamydia trachomatis*</em></p><p><em>Coxiella burnetii Mycoplasma genitalium Mycoplasma hominis</em></p><p><em>Mycoplasma pneumoniae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis* Enterococcus faecium*</em></p><p><em>Staphylococcus aureus </em>(methicillin-resistant)<sup>+</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Enterobacter cloacae</em>* <em>Escherichia coli</em>* <em>Klebsiella pneumoniae</em>*<sup>#</sup></p><p><em>Klebsiella oxytoca</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae*</em><sup>+</sup> <em>Proteus mirabilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis* Peptostreptococcus </em>spp.*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p>#ESBL-producing strains are commonly resistant to fluoroquinolones</p><p>+Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption and Bioavailability</u></p><p style="text-align:justify">Following oral administration moxifloxacin is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.</p><p style="text-align:justify">Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">Moxifloxacin is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. <em>In&nbsp; vitro </em>and <em>ex vivo </em>experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p style="text-align:justify">The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg moxifloxacin:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue</strong></p></td><td style="vertical-align:top"><p><strong>Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Site: Plasma ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma</p></td><td style="vertical-align:top"><p>3.1 mg/l</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Saliva</p></td><td style="vertical-align:top"><p>3.6 mg/l</p></td><td style="vertical-align:top"><p>0.75 - 1.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>1.61 mg/l</p></td><td style="vertical-align:top"><p>1.7<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>5.4 mg/kg</p></td><td style="vertical-align:top"><p>1.7 - 2.1</p></td></tr><tr><td style="vertical-align:top"><p>Alveolar macrophages</p></td><td style="vertical-align:top"><p>56.7 mg/kg</p></td><td style="vertical-align:top"><p>18.6 - 70.0</p></td></tr><tr><td style="vertical-align:top"><p>Epithelial lining fluid</p></td><td style="vertical-align:top"><p>20.7 mg/l</p></td><td style="vertical-align:top"><p>5 - 7</p></td></tr><tr><td style="vertical-align:top"><p>Maxillary sinus</p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Ethmoid sinus</p></td><td style="vertical-align:top"><p>8.2 mg/kg</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyps</p></td><td style="vertical-align:top"><p>9.1 mg/kg</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial fluid</p></td><td style="vertical-align:top"><p>1.02 mg/l</p></td><td style="vertical-align:top"><p>0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Female genital tract*</p></td><td style="vertical-align:top"><p>10.24 mg/kg</p></td><td style="vertical-align:top"><p>1.72<sup>4</sup></p></td></tr></tbody></table><p style="text-align:justify">* intravenous administration of a single 400 mg dose</p><p style="text-align:justify"><sup>1 </sup>10 h after administration</p><p style="text-align:justify"><sup>2 </sup>unbound concentration</p><p style="text-align:justify"><sup>3 </sup>from 3 h up to 36 h post dose 4 at the end of infusion <u>Biotransformation</u></p><p style="text-align:justify">Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p style="text-align:justify">In clinical Phase I and <em>in vitro </em>studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p style="text-align:justify">After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p style="text-align:justify">Concomitant administration of moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p style="text-align:justify"><em>Elderly and patients with low body weight</em></p><p style="text-align:justify">Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.</p><p style="text-align:justify"><em>Renal impairment</em></p><p style="text-align:justify"><em>&nbsp;</em>The pharmacokinetic properties of moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m<sup>2</sup>).</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of moxifloxacin in patients with impaired liver function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of moxifloxacin or after prolonged treatment.</p><p style="text-align:justify">Moxifloxacin, like other quinolones, was genotoxic in <em>in vitro </em>tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In <em>in vivo</em>tests, no evidence of genotoxicity was found despite the fact that very high moxifloxacin doses were used. Thus, a</p><p style="text-align:justify">sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.</p><p style="text-align:justify">Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when&nbsp; tested&nbsp; in&nbsp; a&nbsp; comprehensive&nbsp; programme&nbsp; of <em>in&nbsp; vitro </em>and <em>in&nbsp; vivo </em>studies. Under the same conditions other quinolones induced effects.</p><p style="text-align:justify">At high concentrations, moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.</p><p style="text-align:justify">Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.</p><p style="text-align:justify">Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.</p><p style="text-align:justify">Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, Croscarmellose sodium, Silica colloidal anhydrous, Povidone K-30, Purified water, Magnesium stearate &amp; Opadry pink 03B34285.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>KEEP OUT OF THE REACH OF CHILDREN</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium foil (Hard Tempered) with 7 GSM HSL coating on bright side/ Cold form foil. Pack size: 7 tablets packed in a carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMAN PHARMACEUTICAL PRODUCTS CO. L.L.C. Salalah, Sultanate of Oman
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>